Benham, Rebecca S.
Choi, Catherine
Hodgson, Nathaniel W.
Hewage, Nishani B.
Kastli, Rahel http://orcid.org/0000-0002-3810-6228
Donahue, Rachel J.
Muschamp, John W.
Engin, Elif
Carlezon, William A. Jr. http://orcid.org/0000-0002-4162-3947
Hensch, Takao K. http://orcid.org/0000-0003-0748-8152
Rudolph, Uwe http://orcid.org/0000-0001-9396-4746
Funding for this research was provided by:
McLean Hospital
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (K01MH107787, R01MH063266, 5P50MH094271, R01MH095905)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences (R01ES029097)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
Brain and Behavior Research Foundation (25623)
Whitehall Foundation
Article History
Received: 4 March 2021
Revised: 11 July 2021
Accepted: 27 July 2021
First Online: 18 August 2021
Change Date: 30 August 2017
Change Type: Update
Change Details: The name of the author William A. Carlezon was changed to William A. Carlezon Jr.
Competing interests
: Within the last 2 years, WAC has served as a consultant for Psy Therapeutics, TKH as Scientific Advisor to BrainEver and as Co-Director, Child & Brain Development, Canadian Institute for Advanced Research (CIFAR), and UR as a consultant to Concert Pharmaceuticals. UR is also a Scientific Advisor for Damona Pharmaceuticals. RSB is currently employed by Vertex Pharmaceuticals. WAC is the current Editor-in-Chief of Neuropsychopharmacology.